8 active not recruiting, 3 recruiting, 1 completed, 1 suspended. 13 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Active not recruiting 8, Recruiting 3, Completed 1, Suspended 1 |
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Suspended 1 |
Follow CTLA-4 Antigen: new trials by email Literature Review of CTLA-4 Antigen trials Research Report on CTLA-4 Antigen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma QL1706 (bispecific antibody targeting PD-1 and CTLA-4), Bevacizumab, carboplatin - Ovarian Clear Cell Carcinoma | Phase 3 | Recruiting | Tongji Hospital | 226 | 2025-11-15 | 2026-05-18 |
| Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative Biopsy Procedure, Biospecimen Collection, Computed Tomography - Lung Adenocarcinoma, Lung Adenosquamous Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 427 | 2022-10-07 | 2026-10-01 |
| Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab - Gliosarcoma, MGMT-Unmethylated Glioblastoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 159 | 2020-09-01 | 2026-04-22 |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study Biospecimen Collection, Bone Scan, Cabozantinib - Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1175 | 2019-06-07 | 2026-10-26 |
| Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery Biospecimen Collection, Carboplatin, Computed Tomography - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 / Phase 3 | Suspended | National Cancer Institute (NCI) | 278 | 2019-05-03 | 2026-10-22 |
| Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Ipilimumab, Local Consolidation Therapy, Nivolumab - Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma | Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 339 | 2017-12-29 | 2026-09-18 |
| Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Phase 3 | Active not recruiting | SWOG Cancer Research Network | 275 | 2015-12-29 | 2026-06-09 |
| A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Biospecimen Collection, Computed Tomography, Echocardiography Test - Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 600 | 2015-11-23 | 2026-10-26 |
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Biospecimen Collection, Computed Tomography, Ipilimumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1301 | 2015-11-10 | 2026-10-01 |
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 267 | 2015-09-08 | 2026-10-26 |
| Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b - Melanoma of Unknown Primary, Recurrent Melanoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1673 | 2011-06-17 | 2026-10-22 |
Melanoma (4) · Adenocarcinoma of Lung (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Lung Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Hepatocellular (1) · Clear-cell metastatic renal cell carcinoma (1) · Gliosarcoma (1) · Lymphatic Metastasis (1)
National Cancer Institute (NCI) (8) · SWOG Cancer Research Network (2) · M.D. Anderson Cancer Center (1) · NRG Oncology (1) · Tongji Hospital (1)
United States (12) · Canada (4) · China (1) · Ireland (1) · Puerto Rico (1)
Ahmad Tarhini (1) · Andrew B Lassman (1) · Christine M Bestvina (1) · Frank S Hodi (1) · Jennifer R Eads (1) · Jennifer Y Wo (1) · John V Heymach, MD, PHD (1) · Michael B Atkins (1) · Pedro Barata (1) · Sapna Patel (1) · Tian Zhang (1) · Vassiliki Papadimitrakopoulou (1)
PMID 25649350, PMID 29784747, PMID 32691060, PMID 34264316, PMID 35304832, PMID 35383907, PMID 35613998, PMID 35659704, PMID 36029412, PMID 36166727, PMID 36416836, PMID 37084329, PMID 38152395, PMID 39721752, PMID 40779733
U10CA180820 (4), U10CA180888 (3), U10CA180821 (2), U10CA180868 (2), U24CA196172 (2), P50CA121973 (1), U10CA021115 (1)